In conclusion, miR-7a/b has an anti-fibrotic role in ANG II-treated CFs that is mediated by Sp1 mechanism involving the TGF-β and MAPKs pathways. The gene discussed is SP1; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.